Results 121 to 130 of about 599 (160)

A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod. [PDF]

Infect Dis Ther
Riddler SA, Benson CA, Brinson C, Deeks SG, DeJesus E, Mills A, Para MF, Ramgopal MN, Cai Y, Zheng Y, Zhang L, Jiang W, Liu X, Verrill D, Lim D, de Vries CR, Wallin JJ, Vendrame E, SenGupta D.   +18 more
europepmc   +1 more source

SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1. [PDF]

Emerg Microbes Infect
Wang Q, Guo Y, Schwanz LT, Mellis IA, Sun Y, Qu Y, Urtecho G, Valdez R, Stoneman E, Gordon A, Wang HH, Ho DD, Liu L.   +12 more
europepmc   +1 more source

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy. [PDF]

Front Microbiol, 2017
Iacob SA, Iacob DG.
europepmc   +1 more source

Phenotypic impacts of treatment-selected mutations in HIV-2 protease on darunavir and lopinavir susceptibility: Evaluating genotypic HIV-2 drug resistance tools. [PDF]

PLOS Glob Public Health
Raugi DN, Nixon RS, Smith RA, Hawes SE, Diallo K, Diallo MB, Faye K, Diaw B, Sy MP, Sall F, Seydi M, Gottlieb GS, University of Washington-Senegal HIV-2 Study Group.   +12 more
europepmc   +1 more source

A multiplex method for rapidly identifying viral protease inhibitors. [PDF]

Mol Syst Biol
Hong SJ, Resnick SJ, Iketani S, Cha JW, Albert BA, Fazekas CT, Chang CW, Liu H, Dagan S, Abagyan MR, Fajtová P, Culbertson B, Brace B, Reddem ER, Forouhar F, Glickman JF, Balkovec JM, Stockwell BR, Shapiro L, O'Donoghue AJ, Sabo Y, Freundlich JS, Ho DD, Chavez A.   +23 more
europepmc   +1 more source

Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants. [PDF]

J Infect Dis
Smith RA, Raugi DN, Nixon RS, Seydi M, Margot NA, Callebaut C, Gottlieb GS, University of Washington–Senegal HIV-2 Study Group .   +7 more
europepmc   +1 more source